{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-23-029657","form_type":"8-K","ticker":"MNPR","cik":"0001645469","company_name":"Monopar Therapeutics","filed_at":"2023-11-01T23:59:59+00:00","discovered_at":"2026-05-14T18:03:29.924303+00:00","generated_at":"2026-06-09T02:45:39.172330+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Monopar reports tumor reduction in Phase 1b camsirubicin trial for advanced soft tissue sarcoma at CTOS","bullets":["14 patients enrolled across 5 dose cohorts; 9 of 14 had stable disease per RECIST 1.1.","All patients in cohorts 4 and 5 achieved stable disease; 3 most recent showed ~20% tumor reduction.","One patient with unresectable cancer became eligible for resection after tumor reduction and underwent successful surgery.","No dose-limiting toxicity observed; MTD not yet reached; one LVEF decrease in medically complex patient is being monitored."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-23-029657","json":"https://secwatch.observer/filing/0001437749-23-029657.json","markdown":"https://secwatch.observer/filing/0001437749-23-029657.md","text":"https://secwatch.observer/filing/0001437749-23-029657.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1645469/000143774923029657/0001437749-23-029657-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1645469/000143774923029657/mnpr20231030_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-09T02:45:39.172330+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}